Jeff Moscow, MD
Jeffrey A. Moscow, MD, joined the CTEP Investigational Drug Branch (IDB) in January 2014, after serving part time since August 2012. Prior to joining CTEP, he was Childrenís Miracle Network Professor of Pediatrics, Chief of Pediatric Hematology-Oncology, Vice Chair of Pediatrics, and co-leader of the Experimental Therapeutics Program of the Markey Cancer Center, all at the University of Kentucky. His IDB portfolio includes erlotinib, lapatinib, osimertinib, trebananib, dinutuximab, MEDI570, glembatumumab, and anetumab. Dr. Moscow is the Science Officer of the Phase 2 component of the Early Therapeutics Clinical Trials Network (ETCTN); Program Director of both the Early Drug Development Opportunity Program, a program that helps involve all NCI Cancer Centers in clinical ETCTN research and PDXNet, a Precision Medicine initiative to systematically incorporate patient-derived models into NCIís preclinical drug development efforts. In addition, Dr. Moscow has a laboratory research program in the Urologic Oncology Branch in the NCI Center for Cancer Research that is focused on targeting metabolic pathways for cancer therapy.
National Cancer Institute
9609 Medical Center Dr., MSC 9739
For USPS: Bethesda, MD 20892-9739
For Express and Courier: Rockville, MD 20850
About the Branch Chief
James Zwiebel received the MD degree from the Mount Sinai School of Medicine, where he also completed his residency training in internal medicine. Following a clinical fellowship in hematology and oncology at the George Washington University Medical Center and research fellowships at both the National Cancer Institute and the National Heart Lung and Blood Institute, he continued his laboratory work on cancer gene therapy as a member of the faculty at Lombardi Cancer Center of the Georgetown University Medical Center, where he also practiced hematology and oncology. More…